Literature DB >> 21399745

Individualized pain medicine.

Hyungsuk Kim1, Raymond A Dionne.   

Abstract

Since the first draft of the human genome was published 10 years ago, scientists have tried to develop new treatment strategies for various types of diseases based on individual genomes. It is called personalized (or individualized) medicine and is expected to increase efficacy and reduce adverse reactions of drugs. Much progress has been made with newly developed technologies, though individualized pain medicine is still far from realization. Efforts on the integrative genomic analyses along with understandings of interactions between other related factors such as environment will eventually translate complex genomic information into individualized pain medicine.

Entities:  

Year:  2009        PMID: 21399745      PMCID: PMC3051400          DOI: 10.1016/j.ddstr.2010.10.001

Source DB:  PubMed          Journal:  Drug Discov Today Ther Strateg        ISSN: 1740-6773


  52 in total

Review 1.  Genome-wide association studies for common diseases and complex traits.

Authors:  Joel N Hirschhorn; Mark J Daly
Journal:  Nat Rev Genet       Date:  2005-02       Impact factor: 53.242

2.  The development and impact of 454 sequencing.

Authors:  Jonathan M Rothberg; John H Leamon
Journal:  Nat Biotechnol       Date:  2008-10       Impact factor: 54.908

3.  Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice?

Authors:  Sharon J Gardiner; Evan J Begg
Journal:  Pharmacogenet Genomics       Date:  2005-05       Impact factor: 2.089

4.  COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor.

Authors:  Jon-Kar Zubieta; Mary M Heitzeg; Yolanda R Smith; Joshua A Bueller; Ke Xu; Yanjun Xu; Robert A Koeppe; Christian S Stohler; David Goldman
Journal:  Science       Date:  2003-02-21       Impact factor: 47.728

5.  Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: implication for the adverse effects of cyclooxygenase-2 inhibitors.

Authors:  Xiao-Min Wang; Tian-Xia Wu; Yun-Sil Lee; Raymond A Dionne
Journal:  Clin Pharmacol Ther       Date:  2006-04       Impact factor: 6.875

6.  The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.

Authors:  Lindsey A Criswell; Raymond F Lum; Kevin N Turner; Blanche Woehl; Yuanqing Zhu; Jinyi Wang; Hemant K Tiwari; Jeffrey C Edberg; Robert P Kimberly; Larry W Moreland; Michael F Seldin; S Louis Bridges
Journal:  Arthritis Rheum       Date:  2004-09

Review 7.  Pharmacogenetics of etanercept in rheumatoid arthritis.

Authors:  Maria I Danila; Laura B Hughes; S Louis Bridges
Journal:  Pharmacogenomics       Date:  2008-08       Impact factor: 2.533

8.  Reduced hyperalgesia in homozygous carriers of a GTP cyclohydrolase 1 haplotype.

Authors:  Irmgard Tegeder; Jan Adolph; Helmut Schmidt; Clifford J Woolf; Gerd Geisslinger; Jörn Lötsch
Journal:  Eur J Pain       Date:  2008-04-18       Impact factor: 3.931

9.  Altering gender role expectations: effects on pain tolerance, pain threshold, and pain ratings.

Authors:  Michael E Robinson; Christine M Gagnon; Joseph L Riley; Donald D Price
Journal:  J Pain       Date:  2003-06       Impact factor: 5.820

10.  Lack of influence of GTP cyclohydrolase gene (GCH1) variations on pain sensitivity in humans.

Authors:  Hyungsuk Kim; Raymond A Dionne
Journal:  Mol Pain       Date:  2007-03-07       Impact factor: 3.395

View more
  6 in total

1.  Allelic and genotype frequencies of catechol-O-methyltransferase (Val158Met) and CYP2D6*10 (Pro34Ser) single nucleotide polymorphisms in the Philippines.

Authors:  Michael O Baclig; Rey Z Predicala; Cynthia A Mapua; Jingky P Lozano-Kühne; Maria Luisa G Daroy; Filipinas F Natividad; Francis O Javier
Journal:  Int J Mol Epidemiol Genet       Date:  2012-05-15

Review 2.  Epigenetics and the transition from acute to chronic pain.

Authors:  Thomas Buchheit; Thomas Van de Ven; Andrew Shaw
Journal:  Pain Med       Date:  2012-09-14       Impact factor: 3.750

3.  Sensitivity to μ-opioid receptor-mediated anti-nociception is determined by cross-regulation between μ- and δ-opioid receptors at supraspinal level.

Authors:  J J Ballesta; J Cremades; M Rodríguez-Muñoz; J Garzón; C C Faura
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Neonatal pain: What's age got to do with it?

Authors:  Linda A Hatfield
Journal:  Surg Neurol Int       Date:  2014-11-13

Review 5.  Evidence and consensus recommendations for the pharmacological management of pain in India.

Authors:  Gur Prasad Dureja; Rajagopalan N Iyer; Gautam Das; Jaishid Ahdal; Prashant Narang
Journal:  J Pain Res       Date:  2017-03-29       Impact factor: 3.133

6.  Ultra-High-Precision, in-vivo Pharmacokinetic Measurements Highlight the Need for and a Route Toward More Highly Personalized Medicine.

Authors:  Philip A Vieira; Christina B Shin; Netzahualcóyotl Arroyo-Currás; Gabriel Ortega; Weiwei Li; Arturo A Keller; Kevin W Plaxco; Tod E Kippin
Journal:  Front Mol Biosci       Date:  2019-08-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.